Skip to main content

Advertisement

SpringerLink
Log in

Biologic drugs in the treatment of juvenile dermatomyositis: a literature review

  • REVIEW ARTICLE
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

There is no clear consensus in the literature regarding the choice of biologic therapies and efficacy in juvenile dermatomyositis (JDM). In this review, we aimed to examine previous studies regarding biologic drug use in JDM patients. We screened MEDLINE and Scopus for articles involving JDM patients treated with biologic drugs. We identified 74 articles describing 495 JDM patients treated with biologic drugs (538 biologic treatments) during our literature search. The median (min–max) age of these patients was 9.8 (1–17) years (F/M:1.8). The most frequently used biologic drugs were rituximab (RTX, 50%) and tumor necrosis factor (TNF) inhibitors (34.8%). In a few cases, abatacept (4.3%), anti-interleukin-1 agents (0.9%), tocilizumab (0.9%), bortezomib (0.4%), ustekinumab (0.2%), eculizumab (0.2%), and golimumab (0.2%) were used. RTX was most frequently preferred in patients with severe skin involvement (46.3%). Improvement with RTX was obtained in 60.1% of RTX treatments. Infliximab was most frequently preferred in calcinosis (43.3%), while adalimumab in skin involvement (50%) and etanercept in resistant/recurrent diseases (80%). Improvement was achieved in 44.4% of anti-TNF treatments. Adverse events were observed in 46.8% (58/124) of all treatments. Our results suggest that biologic agents may be a promising alternative for the treatment of particularly resistant JDM cases. Controlled studies are required to provide higher level of evidence for the timing of biologic use in JDM treatment.

Key Points

• There is no consensus on the choice and efficacy of biologic therapies in JDM.

• RTX and TNF inhibitors are the most commonly used biologic drugs.

• Biologics were especially preferred in severe skin involvement, calcinosis, and resistant diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

  1. Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW, Abramson L, Anderson E et al (2018) Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 16(1):84. https://doi.org/10.1186/s12969-018-0299-9

    Article  PubMed  PubMed Central  Google Scholar 

  2. Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K et al (2017) Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the childhood arthritis and rheumatology research alliance in north america. Pediatr Rheumatol Online J 15(1):50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rider LG (2007) The heterogeneity of juvenile myositis. Autoimmun Rev 6(4):241–247. https://doi.org/10.1016/j.autrev.2006.08.009

    Article  CAS  PubMed  Google Scholar 

  4. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62(1):63–72

    Article  PubMed  Google Scholar 

  5. Ramanan AV, Feldman BM (2002) Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14(6):658–662. https://doi.org/10.1097/00002281-200211000-00005

    Article  CAS  PubMed  Google Scholar 

  6. Orandi A, Baszis K, Dharnidharka V, Huber A, Hoeltzel M (2017) Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J 15(1):71. https://doi.org/10.1186/s12969-017-0199-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. De Paepe B, Zschüntzsch J (2015) Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies. Int J Mol Sci 16(8):18683–18713

    Article  PubMed  PubMed Central  Google Scholar 

  8. Boulter EL, Beard L, Ryder C, Pilkington CA (2011) Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis. Pediatr Rheumatol Online J 9(Suppl 1):O29. https://doi.org/10.1186/1546-0096-9-S1-O29

    Article  PubMed Central  Google Scholar 

  9. Prasad S, Misra R, Agarwal V, Lawrence A, Aggarwal A (2013) Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? Int J Rheum Dis 16(5):556–560. https://doi.org/10.1111/1756-185X.12053

    Article  PubMed  Google Scholar 

  10. Perna DL, Callen JP, Schadt CR (2022) Association of treatment with secukinumab with exacerbation of dermatomyositis in a patient with psoriasis. JAMA Dermatol 158(4):454–456. https://doi.org/10.1001/jamadermatol.2021.6011

    Article  PubMed  Google Scholar 

  11. Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA et al (2023) Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. https://doi.org/10.1002/art.42450

    Article  PubMed  Google Scholar 

  12. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Montoya C, Gonzalez M, Ospina F, Tobón G (2017) A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab. J Clin Rheumatol 23(2):129–130. https://doi.org/10.1097/RHU.0000000000000430

    Article  PubMed  Google Scholar 

  14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

    Article  PubMed  PubMed Central  Google Scholar 

  15. Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P et al (2021) JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford) 60(12):5801–5808. https://doi.org/10.1093/rheumatology/keab116

    Article  CAS  PubMed  Google Scholar 

  16. Aeschlimann FA, Frémond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V et al (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain 141(11):e80

    Article  PubMed  Google Scholar 

  17. Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV (2017) Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford) 56(2):247–254

    Article  CAS  PubMed  Google Scholar 

  18. Al-Mayouf SM, AlMutiari N, Muzaffer M, Shehata R, Al-Wahadneh A, Abdwani R et al (2017) Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int 37(9):1513–1517

    Article  PubMed  Google Scholar 

  19. Althagafi HO, Morishita K, Petty RE (2013) Severe vocal cord dysfunction: an unusual complication of juvenile dermatomyositis. J Rheumatol 40(5):744–745

    Article  PubMed  Google Scholar 

  20. Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160(3):520–522. https://doi.org/10.1016/j.jpeds.2011.11.057

    Article  PubMed  PubMed Central  Google Scholar 

  21. Barut K, Aydin POA, Adrovic A, Sahin S, Kasapcopur O (2017) Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol 36(2):361–366. https://doi.org/10.1007/s10067-016-3530-4

    Article  PubMed  Google Scholar 

  22. Besançon A, Brochard K, Dupic L, Gitiaux C, Delville M, Krid S et al (2017) Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology (Oxford) 56(10):1814–1816. https://doi.org/10.1093/rheumatology/kex267

    Article  PubMed  Google Scholar 

  23. Besnard C, Gitiaux C, Girard M, Galmiche-Rolland L, Talbotec C, Quartier P et al (2020) Severe abdominal manifestations in juvenile dermatomyositis. J Pediatr Gastroenterol Nutr 70(2):247–251. https://doi.org/10.1097/MPG.0000000000002575

    Article  PubMed  Google Scholar 

  24. Cannon L, Dvergsten J, Stingl C (2020) Juvenile dermatomyositis and development of malignancy: 2 case reports and a literature review. J Rheumatol 47(3):479

    Article  PubMed  Google Scholar 

  25. Chan Ng PLP, Mopur A, Goh DYT, Ramamurthy MB, Lim MTC, Lim LK et al (2022) Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis 25(2):228–231. https://doi.org/10.1111/1756-185X.14258

    Article  CAS  PubMed  Google Scholar 

  26. Choi RY, Swan RJ, Hersh A, Vitale AT (2018) Retinal manifestations of juvenile dermatomyositis: case report of bilateral diffuse chorioretinopathy with paracentral acute middle maculopathy and review of the literature. Ocul Immunol Inflamm 26(6):929–933. https://doi.org/10.1080/09273948.2017.1305421

    Article  PubMed  Google Scholar 

  27. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56(9):3107–3111. https://doi.org/10.1002/art.22856

    Article  CAS  PubMed  Google Scholar 

  28. Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z et al (2021) Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis 80(4):543–545. https://doi.org/10.1136/annrheumdis-2020-218582

    Article  PubMed  Google Scholar 

  29. Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Pediatr Rheumatol Online J 12:2. https://doi.org/10.1186/1546-0096-12-2

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fotis L, Baszis KW, White AJ, French AR (2016) Four cases of anti-PM/Scl antibody-positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J Rheumatol 43(9):1768–1769. https://doi.org/10.3899/jrheum.151445

    Article  PubMed  Google Scholar 

  31. Hassas Yeganeh M, Ahmadi P, Nilipour Y, Mousavi Khorshidi MS, Sinaei R, Fathi MR et al (2020) A dermatopathic juvenile dermatomyositis; an unexpected case in childhood. Iran J Child Neurol 14(3):89–92

    PubMed  PubMed Central  Google Scholar 

  32. Heinen A, Schnabel A, Brück N, Smitka M, Wolf C, Lucas N et al (2021) Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology (Oxford) 60(4):e136–e138

    Article  PubMed  Google Scholar 

  33. Holzer U, van Royen-Kerkhof A, Van Der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R et al (2010) Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 39(1):88–92. https://doi.org/10.3109/03009740903096622

    Article  CAS  PubMed  Google Scholar 

  34. Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H et al (2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30(1):87–97. https://doi.org/10.1007/s10067-010-1630-0

    Article  PubMed  Google Scholar 

  35. Khan H, Mehta P, Gupta L (2021) Juvenile dermatomyositis with gingival vasculopathy. Clin Rheumatol 40(8):3369–3370

    Article  PubMed  Google Scholar 

  36. Kim LH, Duncan J, Yang CL (2021) Juvenile dermatomyositis and acute respiratory failure in a teen. Chest 160(6):e619–e622

    Article  PubMed  Google Scholar 

  37. Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM (2011) Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 147(7):831–835

    Article  PubMed  Google Scholar 

  38. Lanis A, Volochayev R, Kleiner DE, Vittal A, Heller T, Rider LG et al (2022) Nodular regenerative hyperplasia of the liver in juvenile dermatomyositis. Pediatr Rheumatol Online J 20(1):30. https://doi.org/10.1186/s12969-022-00690-x

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lieberman SM, Sherry DD (2009) Development of classic dermatomyositis rash years after diagnosis of juvenile polymyositis. J Clin Rheumatol 15(6):316–318. https://doi.org/10.1097/RHU.0b013e3181b18cdd

    Article  PubMed  Google Scholar 

  40. Luca NJ, Atkinson A, Hawkins C, Feldman BM (2012) Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J Rheumatol 39(7):1483–1485. https://doi.org/10.3899/jrheum.111592

    Article  PubMed  Google Scholar 

  41. Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel J-L et al (2020) Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology (Oxford) 59(8):1927–1937

    Article  CAS  PubMed  Google Scholar 

  42. Mrosak J, Banasiak K, Edelheit B, Lapin C, Tory H, Collins MS (2021) Polymyxin-B hemoperfusion as a novel treatment for rapidly progressive interstitial lung disease in a pediatric patient diagnosed with anti-MDA5 juvenile dermatomyositis. J Clin Rheumatol 27(8S):S480–S484. https://doi.org/10.1097/RHU.0000000000001191

    Article  PubMed  Google Scholar 

  43. Ochfeld E, Hans V, Marin W, Ahsan N, Morgan G, Pachman LM et al (2022) Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatol 6(1):36. https://doi.org/10.1186/s41927-022-00265-z

    Article  PubMed  PubMed Central  Google Scholar 

  44. Okong’o LO, Esser M, Wilmshurst J, Scott C (2016) Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J 14(1):60. https://doi.org/10.1186/s12969-016-0118-0

    Article  PubMed  PubMed Central  Google Scholar 

  45. Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW (2018) Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 16(1):84. https://doi.org/10.1186/s12969-018-0299-9

    Article  PubMed  PubMed Central  Google Scholar 

  46. Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D (2019) Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain 142(3):e8

    Article  PubMed  PubMed Central  Google Scholar 

  47. Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-González M, Álvarez-Rojas E et al (2021) Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Mod Rheumatol Case Rep 5(1):101–107. https://doi.org/10.1080/24725625.2020.1832755

    Article  PubMed  PubMed Central  Google Scholar 

  48. Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML et al (2014) Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol 32(5):689–696

    PubMed  PubMed Central  Google Scholar 

  49. Riley P, McCann L, Maillard S, Woo P, Murray K, Pilkington C (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47(6):877–880

    Article  CAS  PubMed  Google Scholar 

  50. Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 66(5):783–787. https://doi.org/10.1002/acr.22198

    Article  CAS  PubMed  Google Scholar 

  51. Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L et al (2019) Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain 142(11):e59

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sabbagh SE, Neely J, Chow A, DeGuzman M, Lai J, Lvovich S et al (2021) Risk factors associated with pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology (Oxford) 60(2):829–836

    Article  CAS  PubMed  Google Scholar 

  53. Sallum AME, Silva MFC, Michelin CM, Duarte RJ, Baroni RH, Aikawa NE et al (2011) Penile and scrotum swelling in juvenile dermatomyositis. Acta Reumatol Port 36(2):176–179

    PubMed  Google Scholar 

  54. Sanner H, Sjaastad I, Flatø B (2014) Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 53(9):1578–1585

    Article  CAS  PubMed  Google Scholar 

  55. Schildt EE, De Ranieri D (2021) Anasarca as the presenting symptom of juvenile dermatomyositis: a case series. Pediatr Rheumatol Online J 19(1):120. https://doi.org/10.1186/s12969-021-00604-3

    Article  PubMed  PubMed Central  Google Scholar 

  56. Shimizu M, Inoue N, Takeda Y, Kidouchi K, Fujita N, Fujiki T et al (2021) Concurrent treatment with rituximab and plasma exchange for rapidly progressive interstitial lung disease complicating anti-mda5 antibody-positive juvenile dermatomyositis. J Clin Rheumatol 27(8S):S798–S799. https://doi.org/10.1097/RHU.0000000000001460

    Article  PubMed  Google Scholar 

  57. Sözeri B, Demir F (2020) A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology (Oxford) 59(12):e140–e141

    Article  PubMed  Google Scholar 

  58. Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M et al (2017) Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol 44(4):488–492. https://doi.org/10.3899/jrheum

    Article  PubMed  Google Scholar 

  59. Toplak N, Chavan PP, Rosina S, Dallos T, Semo OR, Aguiar CL et al (2021) Is Anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Case Series. Front Pediatr 9:810785. https://doi.org/10.3389/fped.2021.810785

    Article  PubMed  Google Scholar 

  60. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609. https://doi.org/10.1186/1757-1626-0002-0000006609

    Article  PubMed  PubMed Central  Google Scholar 

  61. Uejima Y, Suganuma E, Kawano Y, Sato S (2020) Anti-MDA5 antibody-positive juvenile dermatomyositis overlap with neuropsychiatric systemic lupus erythematosus: a case report. Clin Exp Rheumatol 39(1):27–28

    PubMed  Google Scholar 

  62. Vaiyani D, Edelson JB, Gmuca S, O’Connor MJ, Mille FK (2021) Juvenile dermatomyositis: a rare but treatable cause of acute myocardial dysfunction. J Clin Rheumatol 27(8S):S777–S778. https://doi.org/10.1097/RHU.0000000000001489

    Article  PubMed  Google Scholar 

  63. Vargas Lebrón C, Ruiz Montesino MD, Moreira Navarrete V, Toyos Sainz de Miera FJ (2020) Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis. Reumatol Clin (Engl Ed) 16(5 Pt 1):368–370. English, Spanish. https://doi.org/10.1016/j.reuma.2018.06.010

  64. Varnier GC, Consolaro A, Maillard S, Pilkington C, Ravelli A (2021) Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. Rheumatology (Oxford) 60(11):5419–5423

    Article  CAS  PubMed  Google Scholar 

  65. Wang C-R (2017) Successful treatment of refractory juvenile dermatomyositis with adalimumab. J Clin Rheumatol 23(3):174–175. https://doi.org/10.1097/RHU.0000000000000514

    Article  CAS  PubMed  Google Scholar 

  66. Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J (2021) Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr Rheumatol Online J 19(1):6

    Article  PubMed  PubMed Central  Google Scholar 

  67. Yeşilbaş O, Yildiz M, Yozgat CY, Tahaoglu I, Yazan H, Cakir E et al (2021) A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis. Turk J Pediatr 63(5):903–908. https://doi.org/10.24953/turkjped.2021.05.018

    Article  PubMed  Google Scholar 

  68. Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G et al (2022) Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J 20(1):60

    Article  PubMed  PubMed Central  Google Scholar 

  69. Horn S, Minden K, Speth F, Schwarz T, Dressler F, Grösch N et al (2022) Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. Clin Exp Rheumatol 40(2):433–442

    Article  PubMed  Google Scholar 

  70. Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn Lucy R et al (2021) The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol 73(7):1253–1266. https://doi.org/10.1002/art.41639

    Article  CAS  PubMed  Google Scholar 

  71. Perron MM, Vasquez-Canizares N, Tarshish G, Wahezi DM (2021) Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies. Pediatr Rheumatol Online J 19(1):92. https://doi.org/10.1186/s12969-021-00574-6

    Article  PubMed  PubMed Central  Google Scholar 

  72. Lerkvaleekul B, Veldkamp SR, van der Wal MM, Schatorjé EJH, Kamphuis SSM, van den Berg JM et al (2022) Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford) 61(5):2144–2155

    Article  CAS  PubMed  Google Scholar 

  73. Stewart JA, Price T, Moser S, Mullikin D, Bryan A (2022) Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J 20(1):16

    Article  PubMed  PubMed Central  Google Scholar 

  74. Yeung TW, Cheong KN, Lau YL, Tse KN (2021) Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J 19(1):103

    Article  PubMed  PubMed Central  Google Scholar 

  75. Hussain A, Rawat A, Jindal AK, Gupta A, Singh S (2017) Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India. Rheumatol Int 37(5):807–812. https://doi.org/10.1007/s00296-017-3707-4

    Article  CAS  PubMed  Google Scholar 

  76. Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA (2020) Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther 22(1):79

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J et al (2022) Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 10:962585

    Article  PubMed  PubMed Central  Google Scholar 

  78. Jin J, Yu H (2022) Use of adalimumab in a child with juvenile dermatomyositis and calcinosis. Indian J Pediatr 89(12):1270. https://doi.org/10.1007/s12098-022-04332-8

    Article  PubMed  Google Scholar 

  79. Gofshteyn J, Mansfield L, Spitznagle J, Balasubramanian P, Cardenas J, Miller T et al (2023) Juvenile dermatomyositis disease activity is associated with the expansion of blood B and T-cell memory subsets lacking follicular markers. Arthritis Rheumatol. https://doi.org/10.1002/art.42446

    Article  PubMed  Google Scholar 

  80. Cancarini P, Nozawa T, Whitney K, Bell-Peter A, Marcuz J-A, Taddio A et al (2022) The clinical features of juvenile dermatomyositis: A single-centre inception cohort. Semin Arthritis Rheum 57:152104. https://doi.org/10.1016/j.semarthrit.2022.152104

    Article  CAS  PubMed  Google Scholar 

  81. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the french autoimmunity and rituximab registry. J Rheumatol 38(7):1436–1440. https://doi.org/10.3899/jrheum.101321

    Article  CAS  PubMed  Google Scholar 

  82. Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases. J Am Acad Dermatol 56(1):148–153. https://doi.org/10.1016/j.jaad.2006.05.068

    Article  PubMed  Google Scholar 

  83. Sukumaran S, Vijayan V (2020) Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol 2020:4073879. https://doi.org/10.1155/2020/4073879

    Article  PubMed  PubMed Central  Google Scholar 

  84. Lilleby V, Haydon J, Sanner H, Krossness BK, Ringstad G, Flatø B (2014) Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. Scand J Rheumatol 43(2):171–173. https://doi.org/10.3109/03009742.2013.863968

    Article  CAS  PubMed  Google Scholar 

  85. Sun C, Lee JH, Yang YH, Yu HH, Wang LC, Lin YT et al (2015) Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol 56(1):31–39

    Article  PubMed  Google Scholar 

  86. Wu Q, Wedderburn LR, McCann LJ (2017) Juvenile dermatomyositis: latest advances. Best Pract Res Clin Rheumatol 31(4):535–557. https://doi.org/10.1016/j.berh.2017.12.003

    Article  PubMed  Google Scholar 

  87. Kuye IO, Smith GP (2017) The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol 16(2):162–166

    CAS  PubMed  Google Scholar 

  88. Marie I, Mouthon L (2011) Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11(1):6–13. https://doi.org/10.1016/j.autrev.2011.06.007

    Article  CAS  PubMed  Google Scholar 

  89. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780–784

    Article  PubMed  PubMed Central  Google Scholar 

  90. Brunasso AM, Aberer W, Massone C (2014) New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal 2014:179180. https://doi.org/10.1155/2014/179180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, et al (2022) Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis. ACR Open Rheumatol 4(11):983–990

  92. Patil A, Lu J, Kassir M, Babaei M, Goldust M (2023) Adult and juvenile dermatomyositis treatment. J Cosmet Dermatol 22(2):395–401. https://doi.org/10.1111/jocd.15363

    Article  PubMed  Google Scholar 

  93. Kul Cinar O, Papadopoulou C, Pilkington CA (2021) Treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 23(2):1–15. https://doi.org/10.1007/s11926-020-00974-9

    Article  Google Scholar 

  94. Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman B et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329–340. https://doi.org/10.1136/annrheumdis-2016-209247

    Article  PubMed  Google Scholar 

  95. Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, CARRA Juvenile Myositis subgroup (2017) Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J 15(1):1–10. https://doi.org/10.1186/s12969-017-0199-4

    Article  Google Scholar 

  96. Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM et al (2015) Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis 9(9):806–815

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None

Funding

No specific funding was received from any bodies in the public, commercial, or not-for-profit sectors to carry out the work described in this article.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Seher Sener, Veysel Cam, Seza Ozen & Ezgi Deniz Batu

Authors
  1. Seher Sener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veysel Cam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seza Ozen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ezgi Deniz Batu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ezgi Deniz Batu.

Ethics declarations

Conflict of interest

Batu ED received payment for speakers’ bureaus from Novartis. Ozen S received consultancy fees and payment for speakers bureaus from Novartis and Sobi. Other authors did not declare any conflicts of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 41.6 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sener, S., Cam, V., Ozen, S. et al. Biologic drugs in the treatment of juvenile dermatomyositis: a literature review. Clin Rheumatol 43, 591–602 (2024). https://doi.org/10.1007/s10067-023-06740-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06740-3

Keywords

Search

Navigation